These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 2171602)
21. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer. Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202 [TBL] [Abstract][Full Text] [Related]
22. [The role of surgical treatment in the combination therapy of small cell lung cancer (SCLC)]. Yamaguchi Y; Momiki S; Kimura H; Ogawa T; Baba M Kyobu Geka; 1988 Mar; 41(3):184-9. PubMed ID: 2838669 [No Abstract] [Full Text] [Related]
23. Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy. Gridelli C; Contegiacomo A; Lauria R; Gentile M; Airoma G; De Placido S; Perrone F; Ferrante G; Bianco AR Tumori; 1991 Dec; 77(6):506-10. PubMed ID: 1666468 [TBL] [Abstract][Full Text] [Related]
24. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698 [TBL] [Abstract][Full Text] [Related]
25. Chemotherapy (CAV) and surgical resection as combined modality in the therapy of small-cell lung cancer. Gatzemeier U; Radenbach D Panminerva Med; 1986; 28(2):63-6. PubMed ID: 3022223 [No Abstract] [Full Text] [Related]
26. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Bunn PA; Greco FA; Einhorn L Semin Oncol; 1986 Sep; 13(3 Suppl 3):45-53. PubMed ID: 3020700 [TBL] [Abstract][Full Text] [Related]
27. [Toxic-allergic lung edema following cyclophosphamide and ifosfamide therapy. Case report]. Kehl A; Bergholz M; von Heyden HW; Nagel GA Onkologie; 1983 Apr; 6(2):84-6. PubMed ID: 6306532 [No Abstract] [Full Text] [Related]
28. Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer. Comis RL Semin Oncol; 1986 Sep; 13(3 Suppl 3):40-4. PubMed ID: 3020699 [TBL] [Abstract][Full Text] [Related]
29. Treatment of small cell lung cancer with cyclophosphamide, adriamycin and vincristine (CAV) combination therapy: experience at University Hospital, Kuala Lumpur, Malaysia. Lee SM Singapore Med J; 1990 Aug; 31(4):317-20. PubMed ID: 2175049 [TBL] [Abstract][Full Text] [Related]
30. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212 [TBL] [Abstract][Full Text] [Related]
31. [Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer]. Saito H; Kawatsu H; Saka H; Yamamoto M; Takagi E; Tsunekawa H; Kawachi H; Nagura E; Sakai S; Nishiwaki K Gan To Kagaku Ryoho; 1988 Jun; 15(6):1909-13. PubMed ID: 2838000 [TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy of small cell lung cancer]. Komiya T; Takada M Gan To Kagaku Ryoho; 1996 Aug; 23(9):1116-23. PubMed ID: 8751797 [TBL] [Abstract][Full Text] [Related]
33. [Polychemotherapy and radiotherapy for small cell cancer of the lung]. Linchenko IF; Danil'ian VM Vopr Onkol; 1983; 29(9):106-14. PubMed ID: 6314659 [No Abstract] [Full Text] [Related]
34. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194 [TBL] [Abstract][Full Text] [Related]
35. Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer. Natale RB; Shank B; Hilaris BS; Wittes RE Am J Med; 1985 Sep; 79(3):303-8. PubMed ID: 2994472 [TBL] [Abstract][Full Text] [Related]
37. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study. Wampler GL; Heim WJ; Ellison NM; Ahlgren JD; Fryer JG J Clin Oncol; 1991 Aug; 9(8):1438-45. PubMed ID: 1649265 [TBL] [Abstract][Full Text] [Related]
38. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Evans WK; Feld R; Murray N; Willan A; Coy P; Osoba D; Shepherd FA; Clark DA; Levitt M; MacDonald A Ann Intern Med; 1987 Oct; 107(4):451-8. PubMed ID: 2820289 [TBL] [Abstract][Full Text] [Related]
39. Protocol cost analysis. Brown JK Prog Clin Biol Res; 1986; 216():199-204. PubMed ID: 3014557 [No Abstract] [Full Text] [Related]
40. [Prevention of bronchopulmonary inflammation in patients with lung cancer receiving cytostatic therapy]. Viazitskiĭ PO; Iakovlev VN; Alekseev VG; Dmitriev IuK; Duganov VK Klin Med (Mosk); 1988 Jun; 66(6):64-7. PubMed ID: 2460668 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]